 HAYWARD, Calif., June 17, 2021 PRNewswire -- AcelRx Pharmaceuticals, Inc. Nasdaq: ACRX, AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has reached agreement with the Food and Drug Administration FDA with regards to finalizing corrective actions AcelRx has taken or plans to take in response to the previously announced FDA warning letter, dated February 11, 2021, regarding certain DSUVIA promotional materials. 